• Emergency Department of Danjiangkou People’s Hospital, Danjiangkou 442007, China;
ZHANG Minxi, Email: 384198970@qq.com
Export PDF Favorites Scan Get Citation

Objective  To evaluate the effectiveness and safety of Dan hong injection for treating diabetic nephropathy (DN).
Methods  We electronically searched CENTRAL (the second issue 2009), MEDLINE (1980-2009.6), EMBASE (1980-2009.6), CNKI (1994-2009.6), CBM (1990-2009.6), WANG FANG (1984-2009.6) and VIP (1989-2009.6) to June 2009, and reference lists of all papers identified also were checked. Randomized controlled trials (RCTs), quasi- RCTs and cross-over studies were identified and assessed according to the Cochrane Handbook for Systematic Reviews of Interventions, and then Revman 5.0 was used to undertake meta analysis.
Results  Ten RCTs of 736 patients of diabetic nephropathy were included. Meta analyses showed that Dan hong injection was superior to routine treatment in decreasing UAER [MD= – 27.08, 95%CI (– 30.40, – 24.02)], Hb1AC [MD= – 1.12, 95%CI (– 1.67, – 0.56)] and FDP [MD= – 2.28, 95%CI (– 2.70, – 1.86)]; and Dan hong had similar effects in reducing the 24 hours proteinuria [MD= – 0.03, 95%CI (– 0.10, 0.04)], serum creatinine [MD= – 1.00, 95%CI (– 7.86, 5.86)], endogenous creatinine clearance rate [MD= – 2.30, 95%CI (– 15.51, 10.91)], blood cholesterol [MD= – 0.10, 95%CI (– 0.68, 0.48)], blood triglyceride [MD= – 0.15, 95%CI (– 0.36, 0.05)] and fasting blood sugar [MD= – 0.10, 95%CI (– 0.68, 0.48)]; However, Dan hong had more effective action on decreasing the UAER [MD= – 13.14, 95%CI (– 18.00, – 8.27)], blood cholesterol (P lt;0.05) and triglyceride (P lt;0.05) comparing with Dan shen, and on reducing 24 hour albuminuria (P lt;0.05) and FDP (P lt;0.05) with Mai luoning; no significant adverse effects or allergic reactions were reported.
Conclusion  Dan hong can improve UAER of DN; conclusive results cannot be made about the effectiveness and safety of dan hong for diabetic nephropathy according to limited existing trials. Larger and higher quality randomized controlled trials are needed to assess the available evidence.

Citation: ZHANG Minxi,CUI Kai,ZHU Yanmin,DUAN Yanpeng. Dan Hong Injection for Diabetic Nephropathy: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2009, 09(10): 1087-1093. doi: 10.7507/1672-2531.20090192 Copy

  • Previous Article

    Efficacy of Peginterferon α-2a in HBeAg Positive Chronic Hepatitis B:Meta-analysis Study
  • Next Article

    Glimepiride Therapy for Type 2 Diabetes Mellitus: A Systematic Review